 |
Hong KongMay 6, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEx: 1672, “Ascletis”) today announced that it will present multiple projects in poster format at the 33rd European Congress on Obesity (ECO 2026), to be held from May 12 to 15, 2026, in Istanbul, Turkey.
Presentations include a poster on Phase I data for ASC47 (a fat-targeted thyroid hormone receptor beta (THRβ) agonist for weight loss without muscle loss), demonstrating up to 111.8% greater relative weight loss in participants with obesity when combined with semaglutide compared to semaglutide monotherapy; and a poster on preclinical data for ASC36 (a once-monthly next-generation amylin receptor agonist peptide), showing an average observed half-life of 32 days in non-human primate models, 6-fold longer than petrelintide, and 91% more relative weight loss than petrelintide in a diet-induced obesity (DIO) rat model.
Presentation Details
Title: ASC47 in Combination with Semaglutide Demonstrated Up to 111.8% Greater Relative Weight Loss in Participants with Obesity Compared to Semaglutide Monotherapy
Session: Track 4: Obesity Management and Intervention (PO4.264)
Date/Time: Thursday, May 14, 2026, 18:00–19:15 Turkey Time (TRT)
Title: ASC36, a Once-Monthly Next-Generation Amylin Receptor Agonist Peptide, Demonstrated 32-day Average Observed Half-life, 6-fold Longer than Petrelintide, in NHP Model and 91% More Relative Weight Loss than Petrelintide in DIO Rat Model
Session: Track 4: Obesity Management and Intervention (PO4.270)
Date/Time: Thursday, May 14, 2026, 18:00–19:15 Turkey Time (TRT)
Title: ASC35, a Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist Peptide, Demonstrated 14-day Average Observed Half-life, 6-fold Longer than Tirzepatide, in NHP Model and 71% More Relative Weight Loss than Tirzepatide in DIO Mouse Model
Session: Track 4: Obesity Management and Intervention (PO4.263)
Date/Time: Thursday, May 14, 2026, 18:00–19:15 Turkey Time (TRT)
For more details about ECO 2026, please visit https://eco2026.org/.
About Ascletis Pharma Inc.
Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of best-in-class and first-in-class drugs for the treatment of metabolic diseases. Leveraging its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP) technology, and Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has independently developed multiple small molecule and peptide drug candidates, including its core program ASC30, an investigational small molecule GLP-1R agonist for both once-daily oral and once-monthly to once-quarterly subcutaneous injection as weight loss therapy and weight maintenance therapy for long-term weight management; ASC36, an amylin receptor agonist peptide; ASC35, a once-monthly subcutaneous GLP-1R/GIPR dual agonist peptide; ASC37, a GLP-1R/GIPR/GCGR triple agonist peptide; ASC39, a potent oral small molecule amylin receptor agonist similar to eloralintide with selectivity for amylin; and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1RA) and ASC39 (amylin receptor agonist) for long-term weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).
For more information, please visit the website: www.ascletis.com.
For inquiries: